Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality DOI Creative Commons
Cheng Han Ng, Zhen Yu Wong, Nicholas Chew

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2022, Volume and Issue: 9

Published: Aug. 8, 2022

Hypertension (HTN) is a common comorbidity in non-alcoholic fatty liver disease (NAFLD) affecting up to 40% of individuals. However, the impact HTN and its control on outcomes NAFLD remains unclear. Therefore, we aimed examine survival longitudinal cohort patients.

Language: Английский

Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity DOI Creative Commons
Min‐Sun Kwak, Donghee Kim

The Korean Journal of Internal Medicine, Journal Year: 2017, Volume and Issue: 33(1), P. 64 - 74

Published: Dec. 5, 2017

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic disease, and prevalence of non-alcoholic steatohepatitis (NASH) with fibrosis increasing as population NAFLD ages. To date, lifestyle modifications including weight loss, increased physical activity, dietary changes remain treatment choice for because there are no approved effective pharmacologic agents. Increased activity has therapeutic effects on by reducing hepatic fat independent reduction. Indeed, even minimal below recommended threshold may have a beneficial impact NAFLD. Aerobic resistance training similar Universal recommendations optimal intensity dose not been established. Therefore, should be tailored based patient’s clinical characteristics, comorbidities, fitness capacity. Physical also prevents development represent valuable strategy public health burden. However, insufficient data supporting progression to NASH advanced fibrosis, extrahepatic disease-related morbidity mortality. In this paper, we review role in management

Language: Английский

Citations

101
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group DOI
Stuart McPherson, Matthew J. Armstrong, Jeremy Cobbold

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2022, Volume and Issue: 7(8), P. 755 - 769

Published: April 28, 2022

Language: Английский

Citations

52
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study DOI
Stephen A. Harrison,

Federico Pérez Manghi,

William B. Smith

et al.

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(7), P. 1432 - 1438

Published: June 20, 2022

Language: Английский

Citations

50
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH DOI Creative Commons

Mathias B. Møllerhøj,

Sanne Skovgård Veidal,

Kirstine Tølbøl Thrane

et al.

Clinical and Translational Science, Journal Year: 2022, Volume and Issue: 15(5), P. 1167 - 1186

Published: Feb. 10, 2022

Abstract Non‐alcoholic steatohepatitis (NASH) has emerged as a major challenge for public health because of high global prevalence and lack evidence‐based therapies. Most animal models NASH sufficient validation regarding disease progression pharmacological treatment. The Gubra‐Amylin (GAN) diet‐induced obese (DIO) mouse demonstrate clinical translatability with respect to etiology hallmarks NASH. This study aimed evaluate responsiveness clinically effective interventions in GAN DIO‐NASH mice. Disease phenotyping was performed male C57BL/6J mice fed the diet fat, fructose, cholesterol 28–88 weeks. biopsy‐confirmed fibrosis received low‐caloric dietary intervention, semaglutide (30 nmol/kg/day, s.c.) or lanifibranor mg/kg/day, p.o.) 8 12 weeks, respectively. Within‐subject change nonalcoholic fatty liver (NAFLD) Activity Score (NAS) stage evaluated using automated deep learning‐based image analysis. showed clear reproducible NASH, stage, tumor burden incidence hepatocellular carcinoma. Consistent trial outcomes, improved NAS, whereas only induced regression stage. Dietary intervention also demonstrated substantial benefits on metabolic outcomes histology. Differential therapeutic efficacy semaglutide, lanifibranor, supported by quantitative histology, RNA sequencing, blood/liver biochemistry. In conclusion, model recapitulates various histological stages faithfully reproduces profiles compounds advanced development Collectively, these features highlight utility preclinical drug development.

Language: Английский

Citations

46
Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality DOI Creative Commons
Cheng Han Ng, Zhen Yu Wong, Nicholas Chew

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2022, Volume and Issue: 9

Published: Aug. 8, 2022

Hypertension (HTN) is a common comorbidity in non-alcoholic fatty liver disease (NAFLD) affecting up to 40% of individuals. However, the impact HTN and its control on outcomes NAFLD remains unclear. Therefore, we aimed examine survival longitudinal cohort patients.

Language: Английский

Citations

46